

**DUPLICATE
ORIGINAL**

Q.B. No. 1639 of 2016

IN THE COURT OF QUEEN'S BENCH OF SASKATCHEWAN
JUDICIAL CENTRE OF SASKATOON

BETWEEN:

FTI CONSULTING CANADA INC., solely in its capacity as court-appointed receiver and manager of all of the assets, undertakings and properties of PHENOMENOME DISCOVERIES INC. and PHENOMENOME LABORATORY SERVICES INC. and not in its personal or corporate capacity

Applicant

- and -

PHENOMENOME DISCOVERIES INC. and
PHENOMENOME LABORATORY SERVICES INC.

Respondents

**IN THE MATTER OF THE RECEIVERSHIP OF PHENOMENOME DISCOVERIES
INC. and PHENOMENOME LABORATORY SERVICES INC.**

APPROVAL AND VESTING ORDER

Before the Honourable Madam Justice A.R. Rothery in Chambers on the 23rd day of September, 2016

UPON THE APPLICATION of the Applicant FTI Consulting Canada Inc. solely in its capacity as court-appointed receiver and manager (in such capacity and not in its personal or corporate capacity, the “**Receiver**”) of all of the assets, undertakings and properties of the Respondents Phenomenome Discoveries Inc. (“**PDI**”) and Phenomenome Laboratory Services Inc. (“**PLSI**” and together with PDI, the “**Company**”) for, *inter alia*, an Order (i) approving the sale transaction (the “**Transaction**”) contemplated by the Purchase and Sale Agreement (the “**Sale Agreement**”) executed August 22, 2016 and made between the Receiver as vendor for and on behalf of the Company and Med-Life Discoveries LP, as purchaser, by its general partner Med-Life Discoveries GP Inc. (and together with its permitted assigns under the Sale Agreement, the “**Purchaser**”), a copy of which is appended as Appendix A to the Confidential Supplement to the Receiver’s Third Report dated August 22, 2016 (the “**Confidential Supplement**”), (ii) vesting in the Purchaser all of the right, title and interest of the Receiver and the Company in and to the Purchased Assets free and clear of all encumbrances other than Permitted Encumbrances (as those terms are defined below) and (iii) granting related relief; AND UPON HAVING READ the Order dated February 25, 2016 appointing the Receiver (the “**Receivership Order**”), the Notice of Application, the Draft Order, the Third Report of the Receiver dated August 22, 2016 the (“**Third Report**”), the Confidential Supplement, the

ORIGINAL
Affidavit of Dayan Goodenowe sworn August 28, 2016, the Affidavit of John Hyshka sworn August 29, 2016, the Supplement to the Third Report of the Receiver dated August 29, 2016 and the Affidavit of Service, all filed; AND UPON hearing the submissions of counsel for the Receiver, counsel for the Purchaser, counsel for Yolbosum Canada Inc. and from any other interested parties who may be present, no one appearing for any other person on the service list, although properly served as appears from the Affidavit of Service;

IT IS HEREBY ORDERED, ADJUDGED AND DECLARED THAT:

Service:

1. The time for service of the Notice of Application for this Order shall be and is hereby abridged and service thereof shall be and is hereby deemed good, timely, valid and sufficient.

Receiver's Conduct:

2. The Receiver's Statement of Receipts and Disbursements for the period from July 8, 2016 to August 13, 2016, as set out in the Third Report, are approved; and
3. The Receiver's actions, conduct and activities, as outlined in the Third Report, are approved.

Sealing:

4. The Clerk of the Court shall file the Confidential Supplement, including the appendices thereto, in a sealed envelope attached to a notice that sets out the style of cause of these proceedings and states that:

THIS ENVELOPE CONTAINS CONFIDENTIAL MATERIALS FILED BY FTI CANADA CONSULTING INC. IN ITS CAPACITY AS THE COURT-APPOINTED RECEIVER AND MANAGER OF THE UNDERTAKING, PROPERTY AND ASSETS OF PHENOMENOME DISCOVERIES INC. AND PHENOMENOME LABORATORY SERVICES INC.; and

THE CONFIDENTIAL MATERIALS ARE SEALED UNTIL FURTHER ORDER OR FILING OF THE RECEIVER'S CERTIFICATE EVIDENCING THE CLOSING OF THE TRANSACTION PURSUANT TO THE ORDER ISSUED BY THE HONOURABLE THE HONOURABLE MADAM JUSTICE A.R. ROTHY ON AUGUST 30, 2016.

5. Application to unseal the Confidential Supplement may be made at any time upon fourteen days' written notice to counsel for the Receiver.

Defined Terms:

6. All capitalized terms not defined herein shall have the respective meanings ascribed to them in the Sale Agreement.

Approval of Transaction:

7. The Sale Agreement and the Transaction are commercially reasonable and in the best interests of the estate of the Company and its stakeholders. The Transaction is hereby approved, and the execution of the Sale Agreement by the Receiver is hereby authorized and approved, *nunc pro tunc*, with such minor amendments as the Receiver may deem necessary.
8. The Receiver is authorized and directed to hold the Deposit, *nunc pro tunc*, and to apply, disburse and/or deliver the Deposit or the applicable portions thereof in accordance with the provisions of the Sale Agreement and this Order.
9. The Receiver and the Purchaser are hereby authorized and directed to take such additional steps and execute such additional documents as may reasonably be necessary or desirable to complete the Transaction and the conveyance of the Purchased Assets to the Purchaser.

Vesting of the Purchased Assets:

10. Upon delivery of a Receiver's certificate to the Purchaser (or its nominee) substantially in the form set out in Schedule "A" hereto (the "Receiver's Certificate"), all of the right, title, interest of the Receiver and the Company in and to the Purchased Assets described in the Sale Agreement and listed on Schedule "B" hereto shall, without further instrument of transfer or assignment, vest absolutely in the Purchaser as contemplated by the Sale Agreement, free and clear of and from any and all security interests (whether contractual, statutory, registered, or otherwise), hypothecs, caveats, interests, mortgages, trusts or deemed trusts (whether contractual, statutory, registered, or otherwise), liens, encumbrances, executions, levies, charges, or other financial or monetary claims, assignments, actions, taxes, judgments, writs of execution, options, agreements, disputes, debts, debentures, easements, covenants, encumbrances or other rights, limitations or restrictions of any nature whatsoever including, without limitation, any rights or interests of any creditors of the Company, whether or not they have attached or have been perfected, registered or filed and whether secured, unsecured, registered or otherwise and whether by payment, set or otherwise, whether liquidated, unliquidated or contingent (collectively "Claims"), including, without limiting the generality of the foregoing:
 - (a) any encumbrances or charges created by the Receivership Order, including, without limitation, the Receiver's Borrowing Charge (as defined in the Receivership Order);
 - (b) any encumbrances or charges created by the Interim Receivership Order, including, without limitation, the Interim Receiver's Borrowing Charge (as defined in the Interim Receivership Order);
and

- (c) all charges, security interests or Claims evidenced by registration, filing or publication pursuant to the *The Personal Property Security Act, 1993* (Saskatchewan) (the “PPSA”) or any other personal property registry system; and
- (d) any Claims held by or in favour of any person served (either directly or through their solicitors) with the Notice of Application, for greater certainty, this Court orders that all of the encumbrances affecting or relating to the Purchased Assets and all charges, security interests and claims evidenced by registrations pursuant to the PPSA are expunged, vacated, and otherwise unconditionally ordered removed, discharged and terminated as against the Purchased Assets, in each case effective as of the applicable date and time of the Receiver’s Certificate.

11. The Receiver is to file with the Court a copy of the Receiver’s Certificate, forthwith after delivery thereof to the Purchaser.

12. No further authorization or approval or any other action by any authority or regulatory body exercising jurisdiction over the Purchased Assets shall be required for the closing and post-closing implementation of the Transaction contemplated in the Sale Agreement.

13. The Purchaser shall be entitled to enter into and upon, hold and enjoy the Purchased Assets for its own use and benefit without any interference of or by any person claiming by or through or against the Company or the Receiver.

14. Upon the registration in the Canadian Intellectual Property Office of a copy of this Order, the applicable Registrar of the Canadian Intellectual Property Office (the “CIPO Registrar”) is hereby directed to transfer all of the right, title and interest of the Company and the Receiver in and to the Purchased Intellectual Property described in the Sale Agreement and listed on Schedule “D” hereto to the Purchaser, free and clear of and from any and all Claims.

15. The Company and all persons or entities who claim by, through or under the Company in respect of the Purchased Assets, save and except for the persons entitled to the benefit of the Permitted Encumbrances, shall stand absolutely and forever barred, estopped, and foreclosed from and permanently enjoined from pursuing, asserting, or claiming any and all estate, right, title, interest, royalty, rental, equity of redemption, or Claim in respect of or to the Purchased Assets and, to the extent that any such persons or entities remain in possession or control of any of the Purchased Assets, or any artifacts or any certificates, instruments or other indicia of title representing or evidencing any right, title, estate or interest in and to the Purchased Assets, they shall forthwith deliver possession thereof to the Purchaser.

16. Immediately after the closing of the Transaction, the holders of the Permitted Encumbrances shall have no claim whatsoever against the Receiver or the Company.

CANCELLATION OF SECURITY REGISTRATIONS:

17. Upon delivery of the Receiver's Certificate, and upon filing of a certified copy of this Order, together with any applicable registration fees, the appropriate Governmental Authorities (as defined below) are hereby directed to register such transfers, assignments, interest authorizations, discharges, discharge statements of conveyances, as may be required to convey clear title to the Purchased Assets to the Purchaser subject only to the Permitted Encumbrances listed on Schedule "C" hereto. Without limiting the foregoing:

- (a) the Registrar of the Personal Property Registry (Saskatchewan) (the "**SK PPR Registrar**") shall and is hereby authorized and directed to cancel and discharge those Claims, if any, other than those Permitted Encumbrances, registered against the estate or interest of Purchaser in and to the Purchased Assets located in the Province of Saskatchewan; and
- (b) the applicable CIPO Registrar shall and is hereby authorized directed to cancel and discharge those Claims, if any, other than those Permitted Encumbrances, registered against the estate or interest of Purchaser in and to the Purchased Intellectual Property described in the Sale Agreement and listed on Schedule "**D**" hereto.

18. The SK PPR Registrar, CIPO Registrar and any other applicable registrar (collectively, the "**Governmental Authorities**") are expressly authorized and directed to include in the discharges of the encumbrances described above all encumbrances registered after the date the Receivership Order was granted.

19. In order to affect the discharges and transfers described above this Court requests that the Governmental Authorities each take such steps as are necessary to give effect to the terms of this Order and the Sale Agreement authorized herein. Presentment of this Order and a copy of the Receiver's Certificate shall be the sole and sufficient authority of the Governmental Authorities to make and register the said transfers and cancel and discharge the registrations of Claims and any encumbrances on the Purchased Assets.

Net Proceeds:

20. The Receiver is authorized and directed, as soon as reasonably practicable following delivery of the Receiver's Certificate, to remit to the applicable counterparty(ies) to each Assigned Contract, the Cure Costs received by the Receiver from the Purchaser.

21. For the purposes of determining the nature and priority of Claims, the net proceeds (following deduction for the Cure Costs (if any are payable) and Transfer Taxes (if any is payable) of and from the sale of the Purchased Assets (the "**Net Proceeds**"))

shall stand in the place and stead of the Purchased Assets, and from and after the delivery of the Receiver's Certificate any encumbrances or charges created by the Receivership Order, including, without limitation, the Receiver's Borrowing Charge and all Claims and encumbrances shall cease to be attached to, encumber or otherwise form a mortgage, security interest, lien or a claim against the Purchased Assets and shall attach to the Net Proceeds from the sale of the Purchased Assets with the same priority as they had with respect to the Purchased Assets immediately prior to the sale, as if the Purchased Assets had not been sold and remained in the possession or control of the person having that possession or control immediately prior to the sale.

22. Notwithstanding:

- (a) the pendency of these proceedings;
- (b) any applications for a bankruptcy order now or hereafter issued pursuant to the *Bankruptcy and Insolvency Act* (Canada) (the "BIA") in respect of the Company and any bankruptcy order issued pursuant to any such applications;
- (c) any assignment in bankruptcy made in respect of the Company; or
- (d) the provisions of any federal or provincial legislation;

the vesting of the Purchased Assets in the Purchaser pursuant to this Order shall be binding on any trustee in bankruptcy that may be appointed in respect of the Company and shall not be void or voidable by creditors of the Company, nor shall it constitute nor be deemed to be a settlement, fraudulent preference, assignment, fraudulent conveyance, transfer at undervalue or other reviewable transactions under the BIA or any other applicable federal or provincial legislation, nor shall it constitute conduct oppressive or unfairly prejudicial conduct pursuant to any applicable federal or provincial legislation.

23. Leave is granted to and the Receiver, the Purchaser and any other interested party, and such parties shall be at liberty to apply for further advice, assistance and directions as may be necessary in order to give full force and effect to the terms of this Order and to assist and aid the parties in closing the Transaction.

Miscellaneous Matters:

24. Pursuant to clause 7(3)(c) of the *Canada Personal Information Protection and Electronic Documents Act* and section 27 of the *Saskatchewan Health Information Protection Act*, the Receiver is authorized and permitted to disclose and transfer to the Purchaser all Transaction Personal Information, including, without limitation, all human resources and payroll information in the Company's records pertaining to the Company's past and current employees. The Purchaser (or its nominee) shall maintain and protect the privacy of such information and shall be entitled to use the personal information provided to it in a manner which is in all material respects identical to the prior use of such information by the Company.

25. The actions taken by the Receiver to date, and in particular the actions and conduct of the Receiver regarding the sale process for the sale of the Purchased Assets and the Transaction, as reported in the Third Report and Confidential Supplement, are hereby approved and ratified and no action shall lie against the Receiver by reason of this Order or the Receivership Order or the performance of any act authorized by this Order or the Receivership Order, except by leave of the Court. The entities related to the Receiver or belonging to the same group as the Receiver shall benefit from the protection arising under the present paragraph.

26. This Honourable Court hereby requests the aid and recognition of any court, tribunal, regulatory or administrative body having jurisdiction anywhere in the world, in Canada or in any of its provinces or territories, and in particular the Province of Saskatchewan, to act in aid of and to be complimentary to this Court in carrying out the terms of this Order, to give effect to this Order and to assist the Receiver and its agents in carrying out the terms of this Order. All courts, tribunals, regulatory and administrative bodies are hereby respectfully requested to make such orders as to provide such assistance to the Receiver, as an officer of the Court, as may be necessary or desirable to give effect to this Order or to assist the Receiver and its agents in carrying out the terms of this Order.

27. This Order must be served only upon those interested parties attending or represented at the within application and service may be effected by facsimile, electronic mail, personal delivery or courier. Service is deemed to be effected the next business day following the transmission or delivery of such documents. Service of this Order on any party not attending this application is hereby dispensed with.

vk 26th vk

ISSUED at the City of Saskatoon, in the Province of Saskatchewan, the ~~16th~~ day of September, 2016

V Groff
Local Registrar

SCHEDULE "A" TO APPROVAL & VESTING ORDER

RECEIVER'S CERTIFICATE

Q.B. No. 1639 of 2016

IN THE COURT OF QUEEN'S BENCH OF SASKATCHEWAN
JUDICIAL CENTRE OF SASKATOON

BETWEEN:

FTI CONSULTING CANADA INC., solely in its capacity as court-appointed receiver and manager of all of the assets, undertakings and properties of PHENOMENOME DISCOVERIES INC. and PHENOMENOME LABORATORY SERVICES INC. and not in its personal or corporate capacity

Applicant

- and -

PHENOMENOME DISCOVERIES INC. and
PHENOMENOME LABORATORY SERVICES INC.

Respondents

**IN THE MATTER OF THE RECEIVERSHIP OF PHENOMENOME DISCOVERIES
INC. and PHENOMENOME LABORATORY SERVICES INC.**

RECEIVER'S CERTIFICATE

RECITALS

- A. Pursuant to an Order of the Honourable Mr. Justice B. J. Scherman of the Court of Queen's Bench of Saskatchewan Judicial District of Saskatoon (the "**Court**") dated February 25, 2016 (the "**Receivership Order**") FTI Consulting Canada Inc. was appointed as the receiver and manager (in such capacity and not in its personal or corporate capacity, the "**Receiver**") of all of the assets, undertakings and properties of Phenomenome Discoveries Inc. ("**PDI**") and Phenomenome Laboratory Services Inc. ("**PLSI**" and together with PDI, the "**Company**").
- B. Pursuant to an Order of the Court September 16, 2016, (the "**Sale Approval Order**") the Court approved the Purchase and Sale Agreement (the "**Sale Agreement**") executed August 22, 2016 and made between the Receiver as vendor for and on behalf of the Company, and not in its personal or corporate capacity, and Med-Life Discoveries LP, as purchaser, by its general partner Med-Life Discoveries GP Inc. (and together with its permitted assigns under the Sale Agreement, the "**Purchaser**") and provided for the

vesting in the Purchaser of all of the right, title and interest of the Receiver and the Company in and to the Purchased Assets, which vesting is to be effective with respect to the Purchased Assets upon the delivery by the Receiver to the Purchaser of a certificate confirming (i) the conditions to closing set out in Sections 8.1 and 8.2 of the Sale Agreement have been satisfied or waived by the Receiver and the Purchaser, and (ii) subject to the delivery of this Certificate, the Transaction has been completed to the satisfaction of the Receiver.

C. Unless otherwise indicated herein, terms with initial capitals have the meanings set out in the Sale Approval Order.

THE RECEIVER CERTIFIES the following:

1. The conditions to closing as set out in Sections 8.1 and 8.2 of the Sale Agreement have been satisfied or waived by the Receiver and the Purchaser.
2. Subject to the delivery of this Certificate, the Transaction has been completed to the satisfaction of the Receiver.

THIS CERTIFICATE was delivered by the Receiver at [●] on [●], 2016.

FTI CONSULTING CANADA INC., solely in its capacity as court-appointed receiver and manager of all of the assets, undertakings and properties of **PHENOMENOME DISCOVERIES INC.** and **PHENOMENOME LABORATORY SERVICES INC.** and not in its personal or corporate capacity

Name: **Jamie Engen**
Title: **Managing Director**

SCHEDULE "B" TO APPROVAL & VESTING ORDER

PURCHASED ASSETS

PDI Assets

Cancer Diagnostic Platform:

1. All tests used to diagnose cancer (including, for greater certainty, colon, ovarian, gastric, liver, prostate, esophageal, breast, lung and endometrial), anti-cancer resistance, and liver and lung metastasis, whether developed and in use or in development, including test kits for the quantitative determination of diagnostic for (i) colorectal cancer referred to as Cologic®, (ii) pancreatic cancer referred to as PanaSee™, and (iii) ovarian cancer referred to as OvAware™;
2. All assets, properties and undertakings owned by PDI and Related to the Business including, without limitation,
 - a. all specimens, samples and freezer inventory relating to cancer diagnostics; and
 - b. all chemical inventory relating to cancer diagnostics;and all those assets properties and undertakings more particularly described in Schedule "F" to the Sale Agreement but, in each case, not including the Excluded Assets.

Neurological Diagnostic Platform:

1. All tests used to diagnose neurological disorders whether developed and in use or in development, including (i) risk assessment kits for Alzheimer's disease including the blood test referred to as AlzID™, and (ii) the diagnostic discovery platform with a pipeline of pre-commercial diagnostic markers in additional diseases including multiple sclerosis, autism, bipolar disorder, schizophrenia, post-stroke pain, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), Parkinson's disease and depression, including all specimens, freezer inventory, samples and chemical inventory related thereto.

Metabolic Biomarker Discovery Platform:

1. The non-targeted metabolomics technology.

Phenomenome Clinical Analyzer Platform:

1. The analytical platform with a 1000 sample/day/system manufactured to ISO 13485:2003 standards, including sample preparation, mass spectrometry, direct patient/doctor reporting and all other parts and software related thereto.

Therapeutic Assets:

1. All drugs, programs and disease modifying targets, whether developed and in use, in development or undergoing clinical trials including those used to treat Alzheimer's disease, Parkinson's disease and Rhizomelic Chondrodysplasia Punctata and the therapy known as Prevene, in each case, including all specimens, freezer inventory, samples and chemical inventory related thereto.

Laboratory Assets:

1. All assets of PDI and/or PLSI Related to the Business, including,
 - a. the Laboratory;
 - b. the Laboratory Licenses;
 - c. all equipment (including computer hardware and software) used in the operation of or in connection with the Laboratory, including, without limitation:
 - i. 2 FTICR including, for greater certainty:
 - (a) 2 7.2T magnets, both requiring maintenance (new seals and shimming);
 - (b) 1 Bruker Apex III that needs electronic repair;
 - (c) 1 Bruker Solarix cart that is fully functional;
 - (d) 1 IRMPD fragmentation unit;
 - (e) Related computers, B-servers, chillers and instrument software;
 - (f) 1 Ionics 3Q dual-source vertically-orientated triple quadrupole mass spectrometer;
 - (g) 1 Gilson 271 autosampler; and
 - (h) Molana software (programmed by PDI) to control the mass spectrometer, autosampler, and results reporting;
 - ii. 1 QTrap;
 - iii. 1 QStar;
 - iv. 4 Agilent HPLC Systems (1100 & 1200);
 - v. 1 Agilent Prep LC System;
 - vi. 1 Agilent 7890 GC/MS System;

- vii. 2 LC-MS Systems (PLSD);
- viii. 10 -80 Freezers;
- ix. 4 Liquid Handling Robots;
- x. 2 Stability Chambers (environmental chamber);
- xi. 1 Micro Balance;
- xii. 2 PCR Machines (Molecular Devices);
- xiii. 1 EP motion robot;
- xiv. 2 -20 Freezers;
- xv. 1 Fridge;
- xvi. 1 Dairy Case;
- xvii. 1 Ice Machine;
- xviii. 6 Centrifuges;
- xix. 2 Biohazard Hoods;
- xx. 1 Autoclave (for tissue culture work);
- xxi. 2 Incubators;
- xxii. 2 Tissue Crushers;
- xxiii. 1 Nitrogen Evaporation System;
- xxiv. 2 Balances;
- xxv. 1 Plate Reader;
- xxvi. 9 Shakers (Mixmate);
- xxvii. 1 Mouse Treadmill;
- xxviii. 1 Piccolo Analyzer;
- xxix. 2 Microscopes;
- xxx. 1 Ampulmatic Sealer;
- xxxi. 2 Barcode Readers;
- xxxii. 2 Ovens; and
- xxxiii. 2 Vapor Systems.

d. all Intellectual Property.

Other Assets:

1. The Purchased Intellectual Property;
2. The Assigned Contracts;
3. The Permits and Licenses;
4. The Books and Records Related to the Business; and
5. All proceeds of any or all of the foregoing received or receivable on or after the Closing Date.

SCHEDULE "C" TO APPROVAL & VESTING ORDER

PERMITTED ENCUMBRANCES

1. Saskatchewan Personal Property Registry Registration #301358515, registered June 30, 2015 in favour of Med-Life Discoveries LP, by its general partner Med-Life Discoveries GP Inc., in the following general property of Phenomenome Discoveries Inc.:
 - (1) 50% OF ALL REVENUES, LESS EXPENSES AGREED TO BY THE SECURED PARTY, IN ANY WAY RESULTING FROM, GENERATED BY OR CONNECTED WITH THE DEBTOR'S PPI-1040 DRUG AND PATENTS RELATED TO RESEARCH, DEVELOPMENT AND APPLICATION THEREOF; AND
 - (2) 50% OF ALL REVENUES IN ANY WAY RESULTING FROM, GENERATED BY OR CONNECTED WITH THE DEBTOR'S VISUALIZING NONTARGETED METABOLOMIC DATA GENERATED FROM FOURIER TRANSFORM ION CYCLOTRON RESONANCE SPECTROMETER ("FTMS") ANALYTIC METHODS AND APPARATUS, ALONG WITH THE DEBTOR'S COLOGIC®, PANASEE™, ALZ-ID™ AND OVAWARE™ DIAGNOSTIC TESTS, AND PATENTS RELATED TO RESEARCH, DEVELOPMENT AND APPLICATION OF FTMS, COLOGIC®, PANASEE™, ALZ-ID™ AND OVAWARE™.AND THE FOLLOWING PROCEEDS: ACCOUNTS, CASH, CHATTEL PAPER, INTANGIBLES, GOODS, INSURANCE PROCEEDS, CHEQUES, DOCUMENTS OF TITLE, INSTRUMENTS, INVESTMENT PROPERTY, TRADE-INS AND ALL OTHER SUBSTITUTIONS OF ANY KIND WHATSOEVER DERIVED DIRECTLY OR INDIRECTLY FROM ANY DEALINGS WITH THE GENERAL COLLATERAL OR PROCEEDS THEREFROM.
2. Saskatchewan Personal Property Registry Registration #301511956, registered July 27, 2016 in favour of Golden Opportunities Fund Inc., in the following general property of Phenomenome Discoveries Inc.:

One (1) Apex Qe Fourier Transform Ion Cyclotron Resonance Mass Spectrometer Vacuum Cart, serial number 12465-96/1 (the "FTMS Vacuum Cart), and One (1) G4270-CTC Analytics HTC PAL Injection System (the "Autosampler"), in priority to any other charges on, or claims to, the FTMS Vacuum Cart or Autosampler granted by the Borrower; and all of the Borrowers' right, title and interest in and to all undertaking and present and after-acquired personal property of whatever nature or kind and wherever situated, including all proceeds (including proceeds of proceeds), but not including:

 - (i) Intellectual Property, including:

- A. The Borrower's name and all business names, trade names, domain names, registered and unregistered trade-marks, service marks and applications therefore currently used or owned by the Borrower;
 - B. All patents, patent applications, and all extensions, reissues, divisionals, continuations, continuations-in-part, and re-examinations thereto, and all inventions and discoveries whether or not patentable currently owned or used by the Borrower in the conduct of its business;
 - C. All copyrights in both published works and unpublished works currently owned or used by the Borrower in the conduct of its business;
 - D. All rights in data, whether or not registerable, of the Borrower;
 - E. All inventions, plans, formulae, methodologies, designs, research data, trade secrets, confidential information, and technology, records, proprietary know-how, drawings, notes, laboratory books and protocols, computer software and documentation, algorithms, sourcecode or procedures relating to or otherwise comprising intellectual property, whether or not in the possession, power and control of the Borrower;
 - F. The right to take action for an infringement of any of these rights;
 - G. Future developments, improvements and refinements to existing intellectual property; and
 - H. Any rights of which the Borrower is a licensee or licensor relating to or otherwise comprising intellectual property;
- (ii) Securities, including any share, stock, warrant, bond, debenture, debenture stock or the like issued by a body corporate or other person that is:
- A. in a form recognized in the area in which it is issued or dealt with as evidencing a share, participation, or other interest in property or in an enterprise, or that evidences an obligation of the issuer; and
 - B. of a type which, in the ordinary course of business, is transferred by delivery with necessary endorsement, assignment and registration in the books of the issuer or agent for the issuer or compliance with the restrictions on transfers; or
- (iii) Securities Accounts, including all of the securities accounts including credit balances, securities entitlements, other financial assets and items or property (or their value) standing to the credit from time to time in such securities accounts; and
- (iv) all proceeds (including proceeds of proceeds) of any of the property specifically excluded above,

but including, without limitation, a Purchase-Money Security Interest in each of the FTMS Vacuum Cart and the Autosampler and in the other collateral where applicable.

SCHEDULE "D" TO APPROVAL & VESTING ORDER

PURCHASED INTELLECTUAL PROPERTY

1. Cologic® trade-mark and all domain names related to the Cologic platform.
2. PanaSee™ trademark and all domain names related to the PanaSee platform.
3. OvAware trademark and all domain names related to the OvAware platform.
4. AlzID trademark and all domain names related to the AlzID platform.
5. All issued, abandoned and application patents on the attached "Phenomenome Discoveries Inc. Patent Histories" report.
6. All not yet drafted and/or filed patents on the attached "Phenomenome Discoveries Inc. Patent Histories" report

Phenomenome Discoveries Inc.
Patent Histories

National Applications										
Name	Inventors	Country	Application No.	Effective Priority Date	Originating PCT	Priority Claims	Publ. Date	Status	Issuance No.	Date of Issuance
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers (LEG-35)										
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Canada	2,476,412	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	2,476,412	19-Feb-08
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	United States (0889444US 1)	10/508,179	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	7,348,143	25-Mar-08
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Australia	2003218548	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	2,003,218.548	19-Jun-08
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Europe	3711734.8	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	1,504,419	4-May-11
		Switzerland	3711734.8					Issued	1,504,419	4-May-11
		Germany	603.37.003.9-08					Issued	1,504,419	4-May-11
		France	3711734.8					Issued	1,504,419	4-May-11
		Netherlands	3711734.8					Issued	1,504,419	4-May-11
		United Kingdom	3711734.8					Issued	1,504,419	4-May-11
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Israel	163617	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	163617	19-Feb-10
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	India	2505/DELNP/2004	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Abandoned	226,252	15-Dec-08
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Iceland	7510	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	abandoned based on cost benefit analysis (instructions given July 22, 2011)		
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Japan	JP2003-579151	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Rejected by examiner; further prosecution not cost effective for the market; instructions to Gowling's not to proceed any further with this application; right to respond to Examiner expired Dec 4/09		
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	South Korea	2004-7014844	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Abandoned	775,559	5-Nov-07
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	New Zealand	534751	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	534,751	13-Sep-07
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Singapore	200104903-7	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	Issued	106,326	31-Aug-06
Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers	Doug Heath and Dayan Goodenowe	Hong Kong	5108864.5	22-Mar-02	PCT/CA2003/000389	US Prov 60/366,277	2-Oct-03	abandoned based on cost benefit analysis (instructions given July 22, 2011)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites (LEG-117)										
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Australia	2006291988	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Issued	2006291988	15-Jun-13
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Australia Divisional	201320105	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Received confirmation of filing divisional application on March 6, 2013		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Brazil		12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		

Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Canada (parent)	2,619,732	12-Sep-06	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Issued	2,619,732	12-Jun-12
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Canada (Divisional)	2,772,688	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Issued Notice of Allowance		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Canada (Divisional 2)	2,881,326	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Date of abandonment - 30 Nov 2015		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	China	200,680,033,461	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Instructions given to abandon on August 5/11; high costs combined with issues in patentability		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Europe	6,817,639.5	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Received Office Action and deadline for responding is June 8, 2013		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Hong Kong	8,107,122.8	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	entered		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	India		12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Abandoned Advice received that subject matter is unpatentable (Aug 26/09)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Japan	2008-529437	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Issued	5038311	13-Jul-12
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Malaysia	PI 20080606	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	New Zealand (parent)	566,252	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	New Zealand (Divisional)	592,021	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Philippines	1-2008-500538	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Singapore (parent)	200801817-2	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	will be allowed to lapse; continued under divisional application		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Singapore (Divisional)	201006597-7	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	issued	165370	29-Jun-12
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Singapore (Divisional #2)	201204131-5	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Abandoned		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	South Korea	2008-7008798	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Ukraine	2008 04643	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for Diagnosing A Colorectal Cancer (CRC) Health State or Change in CRC Health State, or for Diagnosing Risk of Developing CRC or the Presence of CRC in a Subject	Shawn Ritchie and Dayan Goodenowe	United States (08903818US1)	11/910,942	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	Response to OA and Request for Continued Examination filed on September 4, 2012		
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites	Shawn Ritchie and Dayan Goodenowe	Vietnam	1-2008-00905	12-Sep-05	PCT/CA2006/001502	US Prov 60/716,310 US Prov 60/804,764	22-Mar-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (LEG-118)										
Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry	Dayan Goodenowe	Canada	2,621,126	15-Sep-05	PCT/CA2006/001530	US Prov 60/717,378	22-Mar-07	Issued	2,621,126	12-Apr-11
Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry	Dayan Goodenowe	Europe (Validated in Germany, France, Great Britain, Netherland, Sweden and Switzerland)	6804626.7	15-Sep-05	PCT/CA2006/001530	US Prov 60/717,378	22-Mar-07	Issued	1932164	24-Apr-13

Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry	Dayan Goodenowe	Japan	JP2008-530289	15-Sep-05	PCT/CA2006/001530	US Prow 60717,378	22-Mar-07	Issued	5303273	28-Jun-13
Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry	Dayan Goodenowe	United States (08903909US1)	12/060,168	15-Sep-05	PCT/CA2006/001530	US Prow 60717,378	22-Mar-07	Abandoned		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type (LEG-146)										
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Canada (parent)	2620274	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Issued	2,620,274	4-Oct-11
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Europe	7800499.1	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	entered August 21, 2009 Application filed		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Europe Divisional	13100192.4	8-Feb-07	PCT/CA2007/001472	60/888,883	8/14/2009 and publication date for divisional is July 31, 2013	Response to extended search report filed on April 2, 2014		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	United States (08907737US1)	12/030,342	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Issued	9,034,923	18-May-15
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	United States Continuation (08907737US1CON)	12/030,342	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Notice to file missing parts filed on July 13, 2015		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Japan	2009-549551	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Issued	5470050	7-Feb-14
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	India		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Australia	2007346587	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Issued	2007346587	10-Jul-14
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Australia Divisional	2014201707	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Request for examination filed on May 21, 2014		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Hong Kong	9111379.9	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	filed August 10, 2011 based on European divisional application no 10195818.9		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Hong Kong Divisional	1310262.5	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Received confirmation of filing of divisional application		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Israel	200029	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	January 10, 2012 instructions given to abandon application		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	New Zealand	578595	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Singapore (parent)	200665020.4	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	Issued	154236	15-Aug-11
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Singapore (Divisional #1)	201105371-7	8-Feb-07	PCT/CA2007/001472	60/888,883	14-Aug-08	issued	173418	14-Sep-12
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	China		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	South Korea		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Philippines		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Malaysia		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Brazil		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Mexico		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Columbia		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)		

Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Ecuador		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)			
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	South Africa		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)			
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Russian Federation		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)			
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	Egypt		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)			
Methods for the Treatment of Senile Dementia of the Alzheimer's Type	Dayan Goodenowe	United Arab Emirates		8-Feb-07	PCT/CA2007/001472	60/888,883		abandoned based on cost benefit analysis (instructions given July 21, 2009)			
Methods for the Diagnosis of Dementia and other Neurological Disorders (LEG-129)											
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Australia (Parent)	2007219666	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned - application has been continued via divisional filed on December 20, 2013 (2013273746)			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Australia (Divisional)	2013273746	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Request for examination filed			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Brazil	PI 0708321-1	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Canada (Parent)	2,640,748	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	issued	2,640,748	20-Apr-10	
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Canada (Divisional)	2,689,848	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883		Abandoned - instructions given May 14, 2010. Effective date of abandonment Sep 15/10			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	China	2007800070125	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Instructions given to abandon on August 6/11; high costs combined with issues in patentability			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Europe (parent)	7710657.3	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	issued	1922325	30-Nov-11	
		France	7710657.3					issued	1922325	30-Nov-11	
		Germany	60 2007 019 067.3						issued	1922325	30-Nov-11
		Netherlands	7710657.3						issued	1922325	30-Nov-11
		Sweden	7710657.3						issued	1922325	30-Nov-11
		Switzerland	7710657.3						issued	1922325	30-Nov-11
UK	7710657.3						issued	1922325	30-Nov-11		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Europe (Divisional)	10195818.9	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Abandoned			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Europe (Divisional #2)	14187832.2	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Application published on March 25, 2015			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Hong Kong	09108768.5	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued	HK1113160	5-Apr-12	
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Hong Kong Divisional #1		28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Divisional filed			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Hong Kong Divisional #2	15109254.5	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Divisional filed			
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	India	39677KOLNP/2008	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned - methods of diagnosis are not patentable subject matter in India (Dec 9/09)			

Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Japan	JP2008-556622	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued and Published, date of publication is May 21, 2014	5496513	14-Mar-19
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Japan Divisional	JP2012-169181	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued Office Action and deadline for filing response is Aug 5, 2013		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Japan Divisional 2	JP2014-131876	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	application published on October 16, 2014		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Malaysia	P120083207	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Abandoned - instructions given April 2, 2012		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	South Korea	2008-7023687	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	New Zealand (parent)	570413	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued	570413	7-Nov-11
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	New Zealand (Divisional)	593746	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Philippines	1-2008-501943	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Singapore	203805921-4	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued	145198	31-Jan-11
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Ukraine	a 2008 11580	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	United States (08905206US1)	12/280,920	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued	8,304,246	6-Nov-12
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	United States Continuation (08905206US1CON)	13/626,703	26-Sep-12	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	Issued OA		
Methods for the Diagnosis of Dementia and other Neurological Disorders	Lisa Cook and Dayan Goodenowe	Vietnam	1-2008-02343	28-Feb-06	PCT/CA2007/000313	US Prov 60/777,290 US Prov 60/804,779 US Prov 60/888,883	7-Sep-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof (LEG-92)										
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Europe	7710787.8	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Abandoned in August 28, 2013		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Europe Divisional	13176367	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Received notification dated November 13, 2013 that application will be published on December 18, 2013		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	United States (08905214US1)	12/294,215	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Issued and received original certificate of correction	8409794	2-Apr-13
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	United States Continuation (08905214US1CON)	13/801,574	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Abandoned		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Canada	2644330.0	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Abandoned w/ef 23rd March 2016. maintenance fees not paid	2,644,330	
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Japan	JP2009-500679	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Issued	5612303	12-Sep-14
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Japan Divisional	JP2012-259409	23-Mar-07	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Issued and Published	5502972	20-Mar-14
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	India	4094/KOL NP/08	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned - compounds are not novel (instructions given Jan 20, 2010)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Australia	2007231487	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Issued	2007231487	24-Apr-14
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Enn Bingham	Hong Kong	8109943.1	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	entirety; waiting for issuance of European patent		

Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Israel		24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given Nov. 10, 2009)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	South Korea	2008-7026013	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	New Zealand	571134	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Singapore (parent)	200806657-3	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	lapsed April 2011; continued under divisional application		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Singapore (Divisional)	201101506-2	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Issued	P-170061	28-Sep-12
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Vietnam		24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Ukraine	a 2008 12469	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Philippines	1-2008-502157	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Malaysia	PI20083584	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	Abandoned - instructions given May 7, 2012		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	China	2007800188377	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given May 11, 2011)		
Biomarkers Useful for Diagnosing Prostate Cancer, and Methods Thereof	Shawn Ritchie and Erin Bingham	Brazil	PI 0709176-1	24-Mar-06	PCT/CA2007/000469	US Prov. 60/785,480	4-Oct-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof (LEG-99)										
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Europe	7719854.7	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Abandoned effective June 24, 2013		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Europe Divisional	13173408.9	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Received notification dated Sep 4, 2013 indicating that the application will be published on Oct 2, 2013		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Canada	2,851,724	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Issued	2651724	8-Jul-14
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Canada Divisional	2,835,964	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Issued Notice of Allowance		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	United States (08905283US1)	12/301,626	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Application filed		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Japan	2009-511314	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Received Notification of reason for refusal		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Japan Divisional	JP2014-222745	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Application published on March 19, 2015 under publication number P2015-052611A		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	India	4675/KOLNP/2008	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	abandoned - subject matter not patentable in India (instr. Given Jan 7, 2010)		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Australia	2007266218	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Issued	2007266218	15-Jun-13
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Australia Divisional	2013200748	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Request for Examination filed on April 2, 2013		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Hong Kong	9101596.7	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Abandoned effective October 2, 2013		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	Hong Kong Divisional	13111306.1	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Instructions given to file Divisional Application		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenow	South Korea	2008-7028999	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		

Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	New Zealand (parent)	572553	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	New Zealand (divisional)	595121	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Abandoned		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Singapore (parent)	200808317-2	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	will be allowed to lapse; continued under divisional application		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Singapore (Divisional)	201103496-4	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Issued	171691	22-Apr-15
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Brazil	PI 0712812-6	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Diagnosing Multiple Sclerosis and Other Neurological Disorders,	Lisa Cook and Dayan Goodenowe	China	Z 0078E+11	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Instructions given to abandon on August 5/11; high costs combined with issues in patentability		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Malaysia	PI20084722	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	Response to OA filed on October 12, 2012		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Philippines	1-2008-502526	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Ukraine	a 2008 15007	26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof	Lisa Cook and Dayan Goodenowe	Vietnam		26-May-06	PCT/CA2007/000932	60/803,267	6-Dec-07	abandoned based on cost benefit analysis (instructions given May 14, 2009)		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State (LEG-159)										
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	United States (08907442US1)	12/524,641	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Response to Office Action filed on November 26, 2012		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	United States Continuation (08907442US1CON)	14/482158	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Application filed on September 10, 2014		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Canada	2,676,109	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Request for examination filed March 23, 2011		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Europe	8714593-4	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Abandoned		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Europe Divisional	13176355-9	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Patent published on January 8, 2014 with publication number 2682746		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Japan	2009-547508	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Issued	5221566	15-Mar-13
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Japan Divisional	2013-010685	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Received Notice of Decision of Patent Grant		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Australia	2008210207	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Issued	2008210207	28-Aug-14
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Australia Divisional	2014213513	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Application filed on Aug 13, 2014		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Hong Kong	9110723-4	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Abandoned		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Hong Kong Divisional	1410747-8	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	application published on May 16, 2014 under publication number 1188824A		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Singapore	200904824-0	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	January 9, 2012 instructions given to abandon application		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	China	200880009982-30	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Instructions given to abandon on August 5/11; high costs combined with issues in patentability		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	Malaysia	PI 20093031	1-Feb-07	PCT/CA2008/000270	60/887,693	7-Aug-08	Request for examination filed December 1, 2011		
Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	India			PCT/CA2008/000270			Abandoned		

Methods for the Diagnosis of Ovarian Cancer Health States and Risk of Ovarian Cancer Health State	Shawn Ritchie and Erin Bingham	New Zealand	579454	1-Feb-07	PCT/CA2008/000650	60/911,548	7-Aug-08	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging (LEG-133)										
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	United States (09509184US 1)	12/555,178	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Response to OA filed on June 20, 2013		
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Canada	2,690,748	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Issued	2890748	28-Aug-12
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Europe (Validated in Germany, France, Great Britain, Netherland, Sweden and Switzerland)	8748108.1	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Issued	2145181	26-Dec-12
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Japan	2010.502394	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Issued	5220842	15-Mar-13
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Australia	2008238553	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Issued	2008238553	2-Oct-14
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Hong Kong	10101213.7	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Issued	HK1134126	3-May-13
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	New Zealand	579810	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Singapore	200906346-2	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Abandoned		
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Singapore Divisional	201202425-3	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Issued	180208	31-Jul-12
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	Malaysia	PI 20094219	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Instructions given to abandon on February 6, 2012		
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging	Dayan Goodenowe	China	200885011949.4	13-Apr-07	PCT/CA2008/000650	60/911,548	23-Oct-09	Instructions given to abandon on March 30, 2010		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency (LEG-185)										
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Pakistan	11312009	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	abandoned based on cost benefit analysis (instructions given July 6, 2011)		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Saudi Arabia	109.31.0012	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	abandoned based on cost benefit analysis (instructions given July 6, 2011)		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Taiwan	98143152	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	Received Office action		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Thailand	0901095755	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	abandoned based on cost benefit analysis (instructions given July 6, 2011)		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Argentina	20090105048	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	Request for examination filed on October 23, 2012		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Venezuela	002369.2009	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	abandoned based on cost benefit analysis (instructions given July 6, 2011)		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Armin Khan, Paul Wood, Dayan Goodenowe, Rishkesh Mankind, Pearson Ashrafou	Uruguay	32.359	22-Dec-08	n/a	US Prov. 61/139,695	1-Jul-10	abandoned based on cost benefit analysis (instructions given July 6, 2011)		

Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	United States (08912425US1)	13/141.035	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Received a notice of publication of Application from USPTO, republished on May 9, 2013		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Canada	2746831	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Issued	2746831	26-Nov-13
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Europe	9833973.2	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	National entry July 15, 2011		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Japan	2011-541045	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Issued	5740312	May 1 2015
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Japan Divisional		22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10			
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	India	3038/KOLN/2011	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	National entry July 18, 2011		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Australia	2009329784	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Received a request for examination on April 9, 2013		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Hong Kong	11112103.6	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	National entry November 8, 2011		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Israel	213409	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	National entry June 6, 2011		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	New Zealand	593285	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Application abandoned July 24, 2012		
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	Singapore	201104599.4	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Issued	172340	5-May-15
Plasmatogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmatogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenowa, Rishkesh Mankindy, Pearson Ahahonu	China	200980157183.5	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,695	1-Jul-10	Issued Office Action		

Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenawa, Rishkesh Mankindy, Pearson Ahiahonu	South Korea	2011-7012817	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,655	1-Jul-10	National entry July 6, 2011		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenawa, Rishkesh Mankindy, Pearson Ahiahonu	Philippines	12011-581298	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,655	1-Jul-10	National entry June 22, 2011		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenawa, Rishkesh Mankindy, Pearson Ahiahonu	Malaysia	PI 2011002904	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,655	1-Jul-10	Received Office action		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenawa, Rishkesh Mankindy, Pearson Ahiahonu	Brazil	PI 0922519-2	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,655	1-Jul-10	Request for examination filed on November 9, 2012		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenawa, Rishkesh Mankindy, Pearson Ahiahonu	Mexico	MX/a/2011/000795	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,655	1-Jul-10	National entry June 22, 2011		
Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency	Amin Khan, Paul Wood, Dayan Goodenawa, Rishkesh Mankindy, Pearson Ahiahonu	Russian Federation	2011124579	22-Dec-08	PCT/CA2009/001853	US Prov. 61/139,655	1-Jul-10	Issued	2546108	2-Mar-15
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases (LEG-144)										
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	United States (08/08968US)	12/670,426	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Issued	8273575	25-Sep-12
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	US Continuation (08/08968US1CON)	13/694,455	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Abandoned		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Canada	2,693,177	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Received confirmation from Canadian Patent Office that this case should be examined in about 6 months		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Europe	8783279-60	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Entered February 26, 2010, in prosecution		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Japan	2010-517243	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Issued	5306345	5-Jul-13
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Australia	2009280406	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Issued	2006280805	26-Mar-15
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Australian Divisional		26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Request for Examination filed on March 2, 2015		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Hong Kong	10104773-3	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Entered May 14, 2010, waiting issuance of European patent		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	New Zealand	582623	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Abandoned on cost benefit analysis (instructions given Dec 2/11)		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Singapore	201000230-1	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Abandoned		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Singapore Divisional	201204813-8	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Issued	182973	26-Jan-16
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	Malaysia	PI 2010000380	26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115	29-Jan-09	Instructions given to abandon application April 27, 2012		
Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases	Dayan Goodenawa	China		26-Jul-07	PCT/CA2009/001366	US Prov. 60/952,115		Abandoned - instructions given May 14, 2010		
Methods for the Treatment of Elevated Cholesterol Levels (Method for Lowering Cholesterol) (LEG-235); Divisional of LEG-146										
Methods for the Treatment of Elevated Cholesterol Levels	Dayan Goodenawa	Canada - (divisional application of Methods for the Treatment of Senile Dementia of the Alzheimer's Type)	2,695,167	8-Feb-07	PCT/CA2007/001472	60/898,883	14-Aug-08	Issued	2,695,167	1-Nov-11

Methods for the Treatment of Elevated Cholesterol Levels	Dayan Goodenowe	US Continuation (0907737US2CCN)	14663,640	9-Feb-07	PCT/CA2007/001472	60986,693	14-Aug-09	received filing documents		
Methods for the Treatment of Elevated Cholesterol Levels	Dayan Goodenowe	US Divisional (0907737US2)	13526,197	9-Feb-07	PCT/CA2007/001472	60986,693	14-Aug-09	issued	8,993,623	31-Mar-15
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis (LEG-219)										
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Europe	105327797	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,565	3-Feb-11	Application has gone abandoned for failure to pay maintenance fee (due 31 July 2015). The application may be reinstated until Jan 31, 2016. Once this date has passed, the application will be irrevocably abandoned.		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Canada	2769086	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,568	3-Feb-11	Abandoned		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	United States (08914465US1)	13387,110	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,566	3-Feb-11	Abandoned with effect from September 12, 2014		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Japan	2012-521019	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,565	3-Feb-11	Instructions to abandon given on September 5, 2014. Gowlings to advise when abandonment takes effect.		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Australia	2010278641	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,565	3-Feb-11	Office action was issued Dec 5 2014. Final date to respond is Sept 5, 2016. Once the due date has passed with no response, the application will go abandoned.		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	India	213KCLNP/2012	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,566	3-Feb-11	CJ gave instructions to abandon on July 22, 2013 and abandoned on July 29, 2013		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	South Korea	2012-7004627	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,565	3-Feb-11	Instructions to abandon given on September 5, 2014. Gowlings to advise when abandonment takes effect.		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Philippines	1-2012-500194	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,566	3-Feb-11	Abandoned with effect from February 3, 2015		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Brazil	BR 11 2012 001850-7	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,566	3-Feb-11	CJ gave instructions to abandon on July 22, 2013 and abandoned on July 29, 2013		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Mexico	MX/a/2012/001209	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,566	3-Feb-11	abandoned		
Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis	Shawn Ritchie, Dayan Goodenowe, Amin Khan, Pearson Ahiahonu	Russian Federation	2012106596	29-Jul-09	PCT/CA2010/001179	US Prov. 61/229,566	3-Feb-11	CJ gave instructions to abandon on July 22, 2013 and abandoned on July 29, 2013		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis (LEG-224)										
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Eldo Pastura & Shawn Ritchie	United States (08914927US1)	13/499,369	1-Oct-09	PCT/CA2010/001166	US Prov. 61/247,828	7-Apr-11	filed IDS on June 3, 2014		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Eldo Pastura & Shawn Ritchie	Canada	2,774,869	1-Oct-09	PCT/CA2010/001166	US Prov. 61/247,828	7-Apr-11	Prosecution		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Eldo Pastura & Shawn Ritchie	Europe (Validated in Germany, France, Great Britain, Netherland, Sweden and Swiss & Liechtenstein)	10919788	1-Oct-09	PCT/CA2010/001166	US Prov. 61/247,828	7-Apr-11	issued	2483597	6/4/2014

Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Europe Divisional	14164872.5	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Divisional application filed		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Japan	2012-531198	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Issued	5696152	13-Feb-15
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Japan Divisional	2014-165663	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Application published on Dec 25, 2014		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Canada Divisional 1	2,797,960	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Abandoned		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Canada Divisional 2	2,797,941	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Issued	2797941	27-Jan-15
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Australia	2010302509	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Request for Examination filed on April 8, 2013		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Hong Kong	12107891.1	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Issued	HK1157182	10/3/2014
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Hong Kong Divisional	15101636.1	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Application filed on February 13, 2015		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Singapore	201201778-6	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Issued	179122	14-Aug-15
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Singapore Divisional	10201405974S	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Application published on October 30, 2014		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Singapore Divisional#2	10201405975V	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Abandoned		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Swiss and Liechtenstein		1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Received Power of Attorney		
Serum-Based Biomarkers of Pancreatic Cancer and Uses Thereof for Disease Detection and Diagnosis	Elodie Pastural & Shawn Ritchie	Malaysia	PI 2012001448	1-Oct-09	PCT/CA2010/001565	US Prov. 61/247,828	7-Apr-11	Abandoned		
Methods for the Synthesis of Plasmalogens and Plasmalogen Derivatives, and Therapeutic uses thereof (LEG-312)										
Methods For The Synthesis Of Plasmalogens And Plasmalogen Derivatives, And Therapeutic Uses Thereof	M. Amin Khan, Paul Wood, Dayan Goodenowe	Canada	2,812,178		PCT/CA2012/001064	PCT/CA2012/001064	27-Sep-13	Issued	2812178	4-Nov-14
Methods For The Synthesis Of Plasmalogens And Plasmalogen Derivatives, And Therapeutic Uses Thereof	M. Amin Khan, Paul Wood, Dayan Goodenowe	Australia	2012321073		PCT/CA2012/001064	PCT/CA2012/001064		Entered National Phase on April 9, 2013		
Methods For The Synthesis Of Plasmalogens And Plasmalogen Derivatives, And Therapeutic Uses Thereof	M. Amin Khan, Paul Wood, Dayan Goodenowe	United States (08920388US1)	14359098		PCT/CA2012/001064	PCT/CA2012/001064	27-Oct-15	Issued	9,169,280	27-Oct-15
Methods of synthesis of DHA (LEG-271)										
Methods of synthesis of DHA	M. Amin Khan, Paul Wood	Canada	2812126		PCT/CA2012/000239			Maintenance fees not paid Abandoned w.e.f. March 16, 2016	2812126	20-May-14
Methods of synthesis of DHA	M. Amin Khan, Paul Wood	Australia	2012231682		PCT/CA2012/000239			Abandoned w.e.f. March 16, 2015		
Methods of synthesis of DHA	M. Amin Khan, Paul Wood	Europe	12761198.6		PCT/CA2012/000239			Abandoned w.e.f. March 16, 2015		
Methods of synthesis of DHA	M. Amin Khan, Paul Wood	Hong Kong	1410659.4		PCT/CA2012/000239			Abandoned w.e.f. March 16, 2015		
Methods of synthesis of DHA	M. Amin Khan, Paul Wood	Japan	JP2014-500211		PCT/CA2012/000239			Abandoned w.e.f. March 16, 2015		
Methods of synthesis of DHA	M. Amin Khan, Paul Wood	United States (08917017US1)	14066717		PCT/CA2012/000239			Abandoned 03 Feb, 2016		
Methods For The Synthesis Of 13C Labeled DHA And Use As A Reference Standard (LEG-311)										
Methods For The Synthesis Of 13C Labeled DHA And Use As A Reference Standard	M. Amin Khan, Paul Wood, Dayan Goodenowe	Canada	2,812,432	17-Nov-11	PCT/CA2012/001063	US Prov. 61/561,225	23-May-13	Issued	2812432	13-May-14
Methods For The Synthesis Of 13C Labeled DHA And Use As A Reference Standard	M. Amin Khan, Paul Wood, Dayan Goodenowe	Australia	2012323993	17-Nov-11	PCT/CA2012/001063	US Prov. 61/561,225	23-May-13	Entered National Phase on April 12, 2013		
Methods For The Synthesis Of 13C Labeled DHA And Use As A Reference Standard	M. Amin Khan, Paul Wood, Dayan Goodenowe	United States (08920389US1)						Abandoned		
Methods for the Synthesis of 13C Labeled Iodotriecane and use as a Reference Standard (LEG-310)										

Methods For The Synthesis Of 13C Labeled Iodoindane And Use As A Reference Standard	M. Amin Khan, Paul Wood, Dayan Goodenowe	Canada	2812885	17-Nov-11	PCT/CA2012/001055		23-May-13	Issued	2,812,885	29-Jul-14
Methods For The Synthesis Of 13C Labeled Iodoindane And Use As A Reference Standard	M. Amin Khan, Paul Wood, Dayan Goodenowe	Australia	2012318286	17-Nov-11	PCT/CA2012/001055		23-May-13	Issue fees paid on May 6, 2013		
Methods For The Synthesis Of 13C Labeled Iodoindane And Use As A Reference Standard	M. Amin Khan, Paul Wood, Dayan Goodenowe	United States (08920386US1)	14359096		PCT/CA2012/001055			Issued Notice of Allowance		
Methods For The Synthesis Of 13C Labeled Plasmalogen (LEG-309)										
Methods For The Synthesis Of 13C Labeled Plasmalogen	M. Amin Khan, Paul Wood, Dayan Goodenowe	Canada	2812129		PCT/CA2012/001054	PCT/CA2012/001054	23-May-13	Issued	2,812,129	21-Oct-14
Methods For The Synthesis Of 13C Labeled Plasmalogen	M. Amin Khan, Paul Wood, Dayan Goodenowe	Australia	2012321071		PCT/CA2012/001054	PCT/CA2012/001054	23-May-13	Entered National Phase on April 9, 2013		
Methods For The Synthesis Of 13C Labeled Plasmalogen	M. Amin Khan, Paul Wood, Dayan Goodenowe	United States (08920387US1)	14359099		PCT/CA2012/001054	PCT/CA2012/001054		Received Notice of Allowance		

Name of Application	Type of Discovery	Current Patent Stage	Additional Protection Required	Next Critical Date(s)	Further Work Required	Publication Stage
PRE-FILING						
Gastric Cancer Prov 1 (Diagnostics)	molecules that appear to be related to the lipids and plasmalogen families	Not yet drafted	Requires drafting and filing; Elodie is working on the information summary for review by Legal and approval by JH	Oct 1/09 disclosure at conference	No further work required for a filing based on accurate mass, molecular formula and MS/MS data. Some of the molecules of interest may be novel. Further work would be required for a novel compound claim.	Diagnostic Stage 1
Synthesization Method for hydroxylated fatty acids (gTA) (Synthesization)	novel method of synthesizing hydroxylated fatty acids (the gTAs) for use as described in application <i>Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis</i>	Not yet drafted	Requires drafting and filing	Prior to associated therapeutic patent moving to PCT on or before July 10/10	Method is complete. No further research required. Invention summary to be prepared and to pass through the approval process.	Consult with Legal before any publications
Multiple Sclerosis Prov 2 (Diagnostics)	Use of novel hydroxylated fatty acid to diagnose MS (similar to SR's recent filing, this will claim the molecule by its structure for diagnostic use; current application contains invalid gTA structures)	to be determined whether a filing is required	to be determined whether a filing is required	Before PCT filing of Hydroxyl Fatty Acid provisional	Need discussion with SR and DBG as to whether this can be included in the diseases covered by provisional filing <i>Hydroxy Fatty Acid Compounds and Uses Thereof for Disease Treatment and Diagnosis</i> or whether it requires its own filing	Diagnostic Stage 1
Plasmalogen Compound for the Modification of Membrane APP Processing	PLM05 may have potential use as a therapeutic of for the purpose of modifying membrane APP processing. This end result of APP processing modification is the clearance of toxic peptides associated with ADD.	Not yet drafted	Requires drafting and filing, if approved; preliminary draft of information summary form has been received; DBG has required further experiments to be performed.	Before filing of DBG's PCT application for the plasmalogen therapeutic compounds (due Dec 22/09)	Uncertain at this time as to whether this is a new invention, or merely additional biological information on how PLM05 works for the purposes described in DBG's application below, <i>Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency</i> . Email sent to DBG on September 4, 2009 asking for clarification. If this is not a new invention, then additional scientific evidence is support of this new biological information will be added to DBG's patent application at the time of PCT filing. DBG has required additional experiments to be performed. Depending on Dayan's response to the email, may require a further prior art search.	Therapeutics Stage 1

Ovarian Prov 3 (Diagnostics)	Use of diacyls in the diagnosis of ovarian cancer	Not yet drafted	Requires validation, drafting and filing	before transfer to PSI	Currently on hold until we obtain a set of validation samples. Filing required before the method can be transferred to PSI. To avoid use of plasmenyl-PE molecules in the method as they have been claimed in the Shan patent application	Diagnostic Stage 1
Bipolar and Schizophrenia Disease (Diagnostics)	Use of ??? In the diagnosis of bipolar and schizophrenia diseases	Not yet drafted;	Requires drafting and filing	before transfer to PSI	DBG to prepare materials required for Judy to write patent application; filing required before method can be transferred to PSI	Diagnostic Stage 1
Esophageal Cancer Prov 1 (Diagnostics)	Use of ??? In the diagnosis of esophageal cancer	Not yet drafted	Requires completion of the research, drafting and filing; potential issues with data and overlap in contract rights between Osaka and Chiba (see Esophageal)		I have not yet identified markers specific to esophageal cancer in particular (have been looking at a family of markers that appear to be related to gastric cancer in general). Have only one set of FTMS data for esophageal so further data and data mining is required. Requires validation from Chiba (not Osaka) samples, so as to avoid royalty stacking. Not yet known whether molecules of greatest interest will be novel. Requires MS/MS structural information and development of an HST method; issues in developing HTS method because the markers are scattered through different modes	Diagnostic Stage 1
Endometrial/Cervical Cancer Prov 1 (Diagnostics)	Use of ??? In the diagnosis of endometrial and/or cervical cancer	Not yet drafted	Requires drafting and filing, if we are able to develop an HTS method		Requires MS/MS structural information and development of an HST method; issues in developing HTS method because the markers are scattered through different modes	Diagnostic Stage 1
PlsC13 Synthesization Method (Synthesization -- new)	novel method of synthesizing the PlsC13 molecule for use as a standard or as part of a kit, or for research purposes	Not yet drafted	Requires drafting and filing, if approved	Prior to licensing of method to manufacturer	Method is complete. No further research required. Invention summary to be prepared and to pass through the approval process.	Consult with Legal before any publications
Dementia in Dogs (Diagnostic -- new)	use of dementia markers to diagnose risk in companion animals	Not yet drafted	Requires drafting and filing, if Purina is interested in the test	none	Unknown; filing depends upon Purina's interest in the test	Consult with Legal before any publications
PROVISIONAL FILINGS						

Novel starting materials, precursor and route for synthesizing DHA	Invention of certain compounds useful for the synthesis of DHA, as well as a novel process for synthesizing DHA for use as a dietary supplement for the treatment of neurodegenerative and anti-inflammatory diseases	US provisional filed		23-Mar-12		
--------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------	--	-----------	--	--

